Galectin Therapeutics
GALT
60 hedge funds and large institutions have $17.4M invested in Galectin Therapeutics in 2023 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 12 increasing their positions, 8 reducing their positions, and 4 closing their positions.
215% more call options, than puts
Call options by funds: $63K | Put options by funds: $20K
66% more capital invested
Capital invested by funds: $10.5M → $17.4M (+$6.91M)
50% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 8
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
3% more ownership
Funds ownership: 12.22% → 15.21% (+3%)
0% more funds holding
Funds holding: 60 → 60 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Osaic Holdings
Scottsdale,
Arizona
|
+$3.03M |
| 2 |
TCM
Traynor Capital Management
Malvern,
Pennsylvania
|
+$57.1K |
| 3 |
Wealth Enhancement Advisory Services
Plymouth,
Minnesota
|
+$30.7K |
| 4 |
RGF
Retirement Guys Formula
Maumee,
Ohio
|
+$18.9K |
| 5 |
AWM
AE Wealth Management
Topeka,
Kansas
|
+$18.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$72.9K |
| 2 |
AAS
Ameritas Advisory Services
Lincoln,
Nebraska
|
-$64.6K |
| 3 |
Millennium Management
New York
|
-$58.9K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$19.5K |
| 5 |
Neuberger Berman Group
New York
|
-$16.7K |
GALT Hedge Fund Activity: Q3 2023 in Review
60 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q3 2023, worth a combined $17.4M — up 66% from $10.5M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new GALT positions and 4 closed out — a net gain of 1 holder — while 12 added to existing stakes and 8 trimmed.
The largest buyer was Osaic Holdings, adding an estimated $3.03M. The largest seller was BlackRock, cutting an estimated $72.9K.
- 60 institutional investors held Galectin Therapeutics (GALT) as of Q3 2023, unchanged from Q2 2023.
- Funds reported $17.4M of Galectin Therapeutics stock for Q3 2023, up 66% quarter-over-quarter.
- 5 funds opened new Galectin Therapeutics positions in Q3 2023 and 4 closed out, a net change of +1 holder.
- The largest Galectin Therapeutics buyer in Q3 2023 was Osaic Holdings, an estimated $3.03M added.
- The largest Galectin Therapeutics seller in Q3 2023 was BlackRock, an estimated $72.9K sold.
Based on aggregated 13F filings for Q3 2023.